Oncodona

Oncodona
Benefits
Indications

What is the Oncodona Test?

It is the most advanced genetic test for early identification of predisposition to inherited cancer.

Oncodona uses Next Generation Sequencing (NGS) to analyze genetic information present in a panel of 21 genes, including BRCA1 and BRCA2 genes, in order to locate harmful mutations.

The presence of a change or mutation in one of these genes assumes that the female carrier has an increased risk of developing breast and ovarian tumours, or other related cancers.

What is the procedure?

Why use Oncodona test?

The performance of the test, if positive, can be used to adopt follow-up and personalized early detection measures of the patient and their relatives.
Carriers already diagnosed will be more likely to have another type of cancer.
A positive test result may also have important health implications for family members, and even future generations.

What genes are included in the Oncodona test?

In addition to the BRCA1 and BRCA2 genes, the Oncodona test analyzes 19 more genes associated with risk of breast and ovarian cancer, which makes it a more complete test:

Who should use Oncodona test?

Women diagnosed with breast cancer and BRCA1 and BRCA2 negative genetic test. In these typesof patients Oncodona can find a mutation in up to 4% of women.
Women with a family member diagnosed with breast and ovarian cancer.
Women of general population without known increased risk.

Test limitations

It is reported that, in a particular case, the Oncodona test may not identify a mutation in the genes studied, even though a mutation may actually exist in one of the genes.
It is also reported that the Oncodona test can identify changes for which there is currently no medical consensus as to whether such changes pose an increased risk of developing cancer.
The Oncodona test does not include all genes for which the medical literature indicates a possible association with breast and/or ovarian cancer.